{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5fa6db4880850a71c9c4bb45/65298ed1c0e0c90012f88b7b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Emerging MS Clinical Options","description":"<p>Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?</p><p><br></p><p>Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.</p><p><br></p><p>Take our&nbsp;<a href=\"https://elit.dkbmed.com/issues/178/test\" rel=\"noopener noreferrer\" target=\"_blank\">post-test</a>&nbsp;to claim CME credits (https://elit.dkbmed.com/issues/178/test)</p><p>Read this podcast's companion newsletter <a href=\"https://elit.dkbmed.com/issues/176\" rel=\"noopener noreferrer\" target=\"_blank\">here</a>. (https://elit.dkbmed.com/issues/176)</p>","author_name":"eMultipleSclerosis Review"}